Bank of America Securities: Reiterates China Biopharmaceutical's (01177) “Buy” Rating Target Price to HK$3.8
Hehuang Pharmaceutical (00013.HK): ESLIM-01 study results released, long-lasting response rate is impressive
Analysts' Opinions Are Mixed on These Healthcare Stocks: HUTCHMED (HCM) and PAVmed (PAVM)
Yuanda Pharmaceutical (00512.HK): Revenue increased by 10% in 2023, rapid launch of nuclear drugs in the anti-tumor sector
China Biopharmaceutical (1177.HK) Follow-up Review: Self-developed New Drugs Accelerate Implementation, Equity Incentives Promote Long-term Development
Hewang Pharmaceutical (0013.HK) Company Follow-up Review: Sales of furoquintinib exceeded expectations and overseas sales continued to accelerate
Huhuang Pharmaceutical (00013.HK): Fruquintinib sales in the US exceed expectations, are catalytically intensive
UBS: Maintaining Cinda Biotech's (01801) “Buy” Rating Target Price Reduced to HK$57.4
Yuanda Pharmaceutical (00512.HK) First Coverage Report: Multiple Businesses Go Hand in Hand to Lead Development with Nuclear Drugs
UBS: Maintaining Hewang Pharmaceuticals (00013.HK)'s “Buy” Rating and Raising the Target Price to HK$39
Bank Rating | CCB International: Raising Cinda Biotech's Target Price to HK$54.7 to Maintain “Outperform the Market” Rating
CCB International: Maintaining Cinda Biotech's (01801) “Outperform the Market” rating and raising the target price to HK$54.7
Cinda Biotech (1801.HK): Strong revenue growth in the first quarter, various products will be unveiled at the ASCO conference
Nomura Adjusts Pharmaron's Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy
Hehuang Pharmaceutical (0013.HK): Fruquintiniol will be approved soon and can be expected to be released overseas
Nomura Adjusts Asymchem Laboratories' Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy
Minsheng Securities released a research report on April 26 stating that Kanglong Chemical (300759.SZ) was given a recommended rating. The main reasons for the rating include: 1) laboratory services are recovering month-on-month, and new orders for small m
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy
Minsheng Securities released a research report on April 26 stating that it gave Gloria Ying (002821.SZ) a recommended rating. The main reasons for the rating include: 1) rapid revenue growth in the European and American markets, and continued deepening se
CICC: Maintaining Federal Pharmaceuticals (03933.HK)'s “outperforming the industry” rating target price of HK$10.5